Article
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
The Lancet. Oncology - 1 Feb 2023
Rodler Eve, Sharma Priyanka, Barlow William E, Gralow Julie R, Puhalla Shannon L, Anders Carey K, Goldstein Lori, Tripathy Debu, Brown-Glaberman Ursa A, Huynh Thu-Tam, Szyarto Christopher S, Godwin Andrew K, Pathak Harsh B, Swisher Elizabeth M, Radke Marc R, Timms Kirsten M, Lew Danika L, Miao Jieling, Pusztai Lajos, Hayes Daniel F, Hortobagyi Gabriel N
Abstract excerpt
BACKGROUND: Poly(ADP-ribose) polymerase (PARP) inhibitors are effective in germline BRCA1 or BRCA2 (BRCA1/2) mutation-associated metastatic breast cancer. However, studies evaluating PARP inhibitors plus platinum-based chemotherapy in germline BRCA1/2-wildtype triple-negative breast cancer are scarce. A large proportion of germline BRCA1/2-wildtype triple-negative breast cancer shows homologous recombination...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.